Multiple System Atrophy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Diagnosis, By Age, By End User, By Region & Competition, 2021-2031F

The Global Multiple System Atrophy Market is projected to expand from USD 154.39 Million in 2025 to USD 185.53 Million by 2031, reflecting a Compound Annual Growth Rate of 3.11%. This market involves the development and commercialization of both symptomatic treatments and emerging disease-modifying agents aimed at this rare, progressive neurodegenerative disorder. A key factor driving this growth is the refinement of diagnostic protocols combined with heightened clinical awareness, which together are reducing the delay between symptom onset and accurate identification. Supporting this trend of improved detection, the Multiple System Atrophy Trust reported in 2024 that community registrations had increased by 38% since 2020, indicating a significant expansion in the recognized patient population requiring specialized care.

Despite these advances, the market faces a substantial obstacle due to diagnostic ambiguity, as early-stage MSA symptoms often resemble those of Parkinson's disease. This clinical overlap frequently results in misdiagnosis, which severely complicates patient recruitment for clinical trials and elevates the risk of failure for investigational drugs. Consequently, these diagnostic challenges impede the timely introduction of novel therapies to the market, highlighting the persistent need for more distinct diagnostic markers to distinguish MSA from related conditions.

Market Driver

A robust pipeline of novel disease-modifying therapies serves as a primary catalyst for the Global Multiple System Atrophy Market, shifting the industry focus from symptomatic management to potential curative interventions. This momentum is defined by an increasing number of late-stage clinical trials targeting alpha-synuclein pathology, which is central to the disease's progression. For example, Alterity Therapeutics announced in July 2025 that topline data from a Phase 2 trial showed their lead candidate, ATH434, reduced disease progression by approximately 50% compared to historical controls. Highlighting the expanding scale of research, Practical Neurology reported in February 2025 that a new Phase 3 clinical trial was initiated for amlenetug, aiming to enroll over 300 participants across international sites.

Simultaneously, favorable regulatory incentives and Orphan Drug Designations are accelerating market growth by mitigating the financial risks associated with developing treatments for rare neurodegenerative disorders. Regulatory agencies are actively encouraging innovation through expedited review pathways, which are essential for rapidly bringing promising therapies to patients with high unmet needs. A notable example occurred in February 2025, when Lundbeck announced that the U.S. FDA granted Fast Track Designation to amlenetug after Phase 2 data indicated a 37% slower rate of clinical progression in a specific patient subgroup. These milestones not only expedite development timelines but also signal commercial viability to investors, ensuring sustained funding for complex drug programs.

Market Challenge

The diagnostic ambiguity associated with Multiple System Atrophy (MSA) stands as a critical impediment to the global market's expansion. Because early-stage symptoms of MSA, such as motor rigidity and autonomic dysfunction, closely mimic those of Parkinson's disease, patients are frequently misdiagnosed or endure long delays before receiving an accurate confirmation. This clinical uncertainty directly hampers the market by disrupting the drug development pipeline; precise patient identification is essential for the success of clinical trials. When potential candidates are misidentified or diagnosed too late to meet inclusion criteria, recruitment becomes inefficient, and the risk of trial failure increases, which subsequently discourages investment in new therapeutic agents.

The magnitude of this obstacle is significant within the current clinical landscape. According to the International Parkinson and Movement Disorder Society, clinical data from 2024 indicated that misdiagnosis rates for early-stage Multiple System Atrophy ranged between 21% and 38%. This substantial margin of error complicates patient stratification for research purposes, thereby slowing the validation of emerging drugs and delaying the commercial introduction of effective treatments to the patient population.

Market Trends

The adoption of novel neuroimaging and fluid biomarker technologies is fundamentally reshaping the market by transitioning diagnostic protocols from subjective clinical observation to precise biological validation. This trend addresses the sector's most persistent challenge-distinguishing Multiple System Atrophy from similar synucleinopathies-by deploying advanced tools such as seed amplification assays. These technologies are rapidly moving from research settings to commercial availability, enabling earlier patient stratification and reducing the costly failure rates associated with misdiagnosed trial participants. Validating this integration, Mayo Clinic Laboratories announced in a March 2025 press release regarding a partnership with Amprion the launch of the SAAmplify-ɑSYN test, a fluid biomarker assay capable of detecting misfolded alpha-synuclein pathology years before the onset of overt clinical symptoms.

A parallel trend involves the expansion of clinical trials for Neurogenic Orthostatic Hypotension, focusing on the severe autonomic dysfunction that characterizes the disease alongside curative efforts. While disease-modifying agents target underlying neurodegeneration, this trend prioritizes immediate quality-of-life improvements for patients suffering from debilitating blood pressure volatility. Pharmaceutical developers are aggressively advancing late-stage studies for this indication, recognizing the urgent need for durable symptomatic relief. For instance, in an August 2025 corporate update regarding the Phase 3 CYPRESS trial, Theravance Biopharma announced the completion of patient enrollment for ampreloxetine, a therapy designed to treat symptomatic neurogenic orthostatic hypotension in a targeted population of approximately 40,000 U.S. patients.

Key Market Players

• Biohaven Ltd.
• Theravance Biopharma
• Sumitomo Dainippon Pharma Co., Ltd.
• Alterity Therapeutics
• AstraZeneca plc.
• Biogen
• Merck & Co., Inc.
• Neuropore Therapies, Inc.
• WaveBreak Therapeutics
• Newron Pharmaceuticals SPA

Report Scope

In this report, the Global Multiple System Atrophy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Multiple System Atrophy Market, By Diagnosis

• Magnetic Resonance Imaging (MRI)
• Positron Emission Tomography (PET)
• Single Photon Emission Computed Tomography (SPECT)
• Tilt Table Test
• Others

Multiple System Atrophy Market, By Age

• Pediatric
• Adults
• Geriatric

Multiple System Atrophy Market, By End User

• Hospitals
• Ambulatory Surgical Centers
• Others

Multiple System Atrophy Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Multiple System Atrophy Market.

Available Customizations:

Global Multiple System Atrophy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).